Left Atrial Appendage Occlusion in High Bleeding Risk Patients
暂无分享,去创建一个
P. Berne | A. Delitala | P. Mazzone | G. Deiana | G. Casu | G. Viola | G. Lorenzoni | P. Merella | Filomena Sechi | F. Decandia
[1] S. Genovesi,et al. [Atrial fibrillation in severe and end stage renal disease: from oral anticoagulation therapy to percutaneous left atrial appendage occlusion]. , 2019, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
[2] P. Berne,et al. Nonvalvular atrial fibrillation in high-hemorrhagic-risk patients: state of the art of percutaneous left atrial appendage occlusion , 2019, Journal of cardiovascular medicine.
[3] M. Lombardi. Due comunicazioni di Nefrologia Narrativa presentate al convegno della Società Italiana di Nefrologia di Rimini 2018 , 2018, Giornale di Tecniche Nefrologiche e Dialitiche.
[4] N. Kounis,et al. Device‐associated thrombus formation after left atrial appendage occlusion , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] F. Pieruzzi,et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. , 2018, International journal of cardiology.
[6] Tzeng-Ji Chen,et al. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[7] J. Mayet,et al. Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis , 2018, Open Heart.
[8] Xavier Freixa,et al. Device‐associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[9] S. Kische,et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[10] A. Delitala. Subclinical Hyperthyroidism and the Cardiovascular Disease , 2017, Hormone and Metabolic Research.
[11] S. Kische,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.
[12] J. Graff‐Radford,et al. Cerebral Amyloid Angiopathy: Diagnosis, Clinical Implications, and Management Strategies in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[13] S. Themistoclakis,et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training , 2017, European heart journal supplements : journal of the European Society of Cardiology.
[14] S. Genovesi,et al. Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease , 2017, Cardiorenal Medicine.
[15] J. Nielsen-Kudsk,et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] L. Madsen,et al. Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark , 2017, Scandinavian journal of gastroenterology.
[17] Ulrich Schotten,et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.
[18] M. Táborský,et al. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Souhrn dokumentu připravený Českou kardiologickou společností , 2016 .
[19] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[20] S. Themistoclakis,et al. [ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus document: Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: indications, patient selection, competences, organization, and operator training]. , 2016, Giornale italiano di cardiologia.
[21] S. Ge,et al. Chronic Kidney Disease and the Risk of New-Onset Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies , 2016, PloS one.
[22] M. Ozdemir,et al. Dabigatran Versus Warfarin in Atrial Fibrillation , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[23] B. Meier,et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[24] S. Kische,et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.
[25] J. Saw. Amplatzer Cardiac Plug and Amulet , 2016 .
[26] Hugh Calkins,et al. Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation. , 2015, Journal of the American College of Cardiology.
[27] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[28] B. Meier,et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[29] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[30] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[31] D. Singer,et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. , 2013, The American journal of cardiology.
[32] C. Cannon,et al. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting , 2013, Clinical cardiology.
[33] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.
[34] S. Doggrell. More light at the end of the tunnel – apixaban in atrial fibrillation , 2012, Expert opinion on investigational drugs.
[35] W. Marsden. I and J , 2012 .
[36] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[37] Saibal Kar,et al. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.
[38] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[39] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[40] G. Lip,et al. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial , 2010, Expert opinion on pharmacotherapy.
[41] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[42] Stephen S. Cha,et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.
[43] A. Hofman,et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.
[44] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.